GlobeNewswire: Novan, Inc. Contains the last 10 of 182 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:55:57ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/07/17/2705615/0/en/Novan-Enters-into-Agreement-to-Sell-Substantially-All-of-its-Assets-including-Berdazimer-Gel-10-3-SB206-and-Files-for-Chapter-11-Protection.html?f=22&fvtc=4&fvtv=29956Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection2023-07-17T12:45:25Z<![CDATA[– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing –]]>https://www.globenewswire.com/news-release/2023/06/05/2682015/0/en/Novan-to-Provide-Corporate-Update-at-its-2023-Annual-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=29956Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders 2023-06-05T13:00:00Z<![CDATA[DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format.]]>https://www.globenewswire.com/news-release/2023/05/31/2679792/0/en/Novan-Focuses-Strategic-Direction-and-Announces-Restructuring.html?f=22&fvtc=4&fvtv=29956Novan Focuses Strategic Direction and Announces Restructuring2023-05-31T20:05:00Z<![CDATA[– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum –]]>https://www.globenewswire.com/news-release/2023/05/15/2668563/0/en/Novan-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=29956Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update2023-05-15T10:45:00Z<![CDATA[– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) –]]>https://www.globenewswire.com/news-release/2023/05/08/2663387/0/en/Novan-to-Report-First-Quarter-2023-Financial-Results-on-May-15-2023.html?f=22&fvtc=4&fvtv=29956Novan to Report First Quarter 2023 Financial Results on May 15, 20232023-05-08T13:05:00Z<![CDATA[DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.]]>https://www.globenewswire.com/news-release/2023/04/27/2656480/0/en/Novan-Announces-Publication-of-Psoriasis-Patient-Data-Demonstrating-Need-for-Rapid-Symptom-Improvement.html?f=22&fvtc=4&fvtv=29956Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹2023-04-27T13:10:00Z<![CDATA[Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1]]>https://www.globenewswire.com/news-release/2023/04/20/2651079/0/en/Novan-to-Host-Analyst-and-Investor-Event-A-Discussion-of-Molluscum-s-Unmet-Need-with-Pediatric-Dermatologist-Jeffrey-Sugarman-MD-PhD.html?f=22&fvtc=4&fvtv=29956Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD2023-04-20T13:00:00Z<![CDATA[Live moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday, April 25th at 2:00 PM ET Live moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday, April 25th at 2:00 PM ET]]>https://www.globenewswire.com/news-release/2023/03/30/2637448/0/en/Novan-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=29956Novan Reports Full Year 2022 Financial Results and Provides Corporate Update2023-03-30T10:30:00Z<![CDATA[– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 –]]>https://www.globenewswire.com/news-release/2023/03/23/2633216/0/en/Novan-to-Report-Full-Year-2022-Financial-Results-on-March-30-2023.html?f=22&fvtc=4&fvtv=29956Novan to Report Full Year 2022 Financial Results on March 30, 20232023-03-23T13:00:00Z<![CDATA[DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day.]]>https://www.globenewswire.com/news-release/2023/03/16/2629197/0/en/Novan-Announces-Closing-of-6-0-Million-Registered-Direct-Offering.html?f=22&fvtc=4&fvtv=29956Novan Announces Closing of $6.0 Million Registered Direct Offering2023-03-16T20:15:00Z<![CDATA[DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company’s previously announced registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share (or pre-funded warrant) and associated Common Warrant. The Common Warrants will become exercisable six months from the date of issuance at an exercise price of $1.20 per share and will expire five years following the initial exercise date.]]>